The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Diabetes Mellitus and Breast Cancer Outcomes: A Systematic Review and Meta-Analysis
Open accessAbstract
Purpose: The goal of this study was to perform a systematic review and meta-analysis to examine the effect of pre-existing diabetes on breast cancer–related outcomes. Methods: We searched EMBASE and MEDLINE databases from inception through July 1, 2009, using search terms related to diabetes mellitus, cancer, and prognostic outcome. Studies were included if they reported a prognostic outcome by diabetes status, evaluated a cancer population, and contained original data published in the English language. We performed a meta-analysis of pre-existing diabetes and its effect on all-cause mortality in patients with breast cancer and qualitatively summarized other prognostic outcomes. Results: Of 8,828 titles identified, eight articles met inclusion/exclusion criteria and described outcomes in patients with breast cancer and diabetes. Pre-existing diabetes was significantly associated with all-cause mortality in six of seven studies. In a meta-analysis, patients with breast cancer and diabetes had a significantly higher all-cause mortality risk (pooled hazard ratio [HR], 1.49; 95% CI, 1.35 to 1.65) compared with their nondiabetic counterparts. Three of four studies found pre-existing diabetes to be associated with more advanced stage at presentation. Diabetes was also associated with altered regimens for breast cancer treatment and increased toxicity from chemotherapy. Conclusion: Compared with their nondiabetic counterparts, patients with breast cancer and pre-existing diabetes have a greater risk of death and tend to present at later stages and receive altered treatment regimens. Studies are needed to investigate pathophysiologic interactions between diabetes and breast cancer and determine whether improvements in diabetes care can reduce mortality in patients with breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., Vandenbroucke, J. P., & Initiative, F. T. S. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040296 · Cited by 23,020
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., Vandenbroucke, J. P., & Initiative, F. T. S. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-8-200710160-00010 · Cited by 17,796
Duval, S., & Tweedie, R. (2000) · Biometrics · doi:10.1111/j.0006-341x.2000.00455.x · Cited by 14,099
Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms
Calle, E. E., & Kaaks, R. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1408 · Cited by 3,613
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., & Vandenbroucke, J. P. (2007) · Preventive Medicine · doi:10.1016/j.ypmed.2007.08.012 · Cited by 2,698
Systematic review and meta-analysis
(2019) · Providing Information for Health · doi:10.1201/9781315377315-19 · Cited by 2,659
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., & Vandenbroucke, J. P. (2007) · Epidemiology · doi:10.1097/ede.0b013e3181577654 · Cited by 1,991
Insulin-like growth factors and neoplasia
Pollak, M. N., Schernhammer, E. S., & Hankinson, S. E. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1387 · Cited by 1,463
Effect of Age and Comorbidity in Postmenopausal Breast Cancer Patients Aged 55 Years and Older
Yancik, R. (2001) · JAMA · doi:10.1001/jama.285.7.885 · Cited by 896
Barone, B. B. (2008) · JAMA · doi:10.1001/jama.2008.824 · Cited by 881
Self-citationJiralerspong, S., Palla, S. L., Giordano, S. H., Meric-Bernstam, F., Liedtke, C., Barnett, C. M., Hsu, L., Hung, M.-C., Hortobagyi, G. N., & Gonzalez-Angulo, A. M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.19.6410 · Cited by 880
Alimova, I. N., Liu, B., Fan, Z., Edgerton, S. M., Dillon, T., Lind, S. E., & Thor, A. D. (2009) · Cell Cycle · doi:10.4161/cc.8.6.7933 · Cited by 523
Obesity and cancer risk: the role of the insulin-IGF axis
Renehan, A. G., Frystyk, J., & Flyvbjerg, A. (2006) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2006.08.006 · Cited by 480
Mortality Trends in Men and Women with Diabetes, 1971 to 2000
Gregg, E. W., Gu, Q., Cheng, Y. J., Venkat Narayan, K. M., & Cowie, C. C. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-3-200708070-00167 · Cited by 463
Comorbidity and Survival Disparities Among Black and White Patients With Breast Cancer
Tammemagi, C. M. (2005) · JAMA · doi:10.1001/jama.294.14.1765 · Cited by 432
Diabetes mellitus and breast cancer
Wolf, I., Sadetzki, S., Catane, R., Karasik, A., & Kaufman, B. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)01736-5 · Cited by 422
van de Poll‐Franse, L. V., Houterman, S., Janssen‐Heijnen, M. L. G., Dercksen, M. W., Coebergh, J. W. W., & Haak, H. R. (2007) · International Journal of Cancer · doi:10.1002/ijc.22532 · Cited by 324
Insulin-Lowering Effects of Metformin in Women with Early Breast Cancer
Goodwin, P. J., Pritchard, K. I., Ennis, M., Clemons, M., Graham, M., & Fantus, I. G. (2008) · Clinical Breast Cancer · doi:10.3816/cbc.2008.n.060 · Cited by 228
Srokowski, T. P., Fang, S., Hortobagyi, G. N., & Giordano, S. H. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.5935 · Cited by 222
Metformin in Breast Cancer: Time for Action
Goodwin, P. J., Ligibel, J. A., & Stambolic, V. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.1630 · Cited by 200
Expanding Priorities — Confronting Chronic Disease in Countries with Low Income
Anderson, G. F., & Chu, E. (2007) · New England Journal of Medicine · doi:10.1056/nejmp068182 · Cited by 197
Sulphonylureas and cancer: a case-control study
Monami, M., Lamanna, C., Balzi, D., Marchionni, N., & Mannucci, E. (2009) · Acta Diabetologica · doi:10.1007/s00592-008-0083-2 · Cited by 194
The impact of diabetes on survival following breast cancer
Lipscombe, L. L., Goodwin, P. J., Zinman, B., McLaughlin, J. R., & Hux, J. E. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9654-0 · Cited by 176 · cited 2×
“We considered studies to be of higher quality and calculated separate random-effects pooled HRs if they were population based (n 4)(6,17-19) or used medical records or medication use for diabetes ascertainment (n 4)(17,18,20,21) and evaluated diabetes as the primary exposure variable (n 3).(6,18,19) We also calculated…”
BackgroundMethodChapman, J.-A. W., Meng, D., Shepherd, L., Parulekar, W., Ingle, J. N., Muss, H. B., Palmer, M., Yu, C., & Goss, P. E. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn014 · Cited by 175
Bowker, S. L., Yasui, Y., Veugelers, P., & Johnson, J. A. (2010) · Diabetologia · doi:10.1007/s00125-010-1750-8 · Cited by 165
Comorbidity as a Predictor of Stage of Illness for Patients With Breast Cancer
Fleming, S. T., Pursley, H. G., Newman, B., Pavlov, D., & Chen, K. (2005) · Medical Care · doi:10.1097/00005650-200502000-00006 · Cited by 158
Obesity and Mammography: A Systematic Review and Meta-Analysis
Maruthur, N. M., Bolen, S. D., Brancati, F. L., & Clark, J. M. (2009) · Journal of General Internal Medicine · doi:10.1007/s11606-009-0939-3 · Cited by 144
Self-citationIs it Time to Test Metformin in Breast Cancer Clinical Trials?
Cazzaniga, M., Bonanni, B., Guerrieri‐Gonzaga, A., & DeCensi, A. (2009) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-08-0871 · Cited by 134
Fleming, S. T., Rastogi, A., Dmitrienko, A. A., & Johnson, K. D. (1999) · Medical Care · doi:10.1097/00005650-199906000-00009 · Cited by 119
Du, W., & Simon, M. S. (2005) · Breast Cancer Research and Treatment · doi:10.1007/s10549-005-0324-9 · Cited by 90
Screening Mammogram Utilization in Women With Diabetes
Beckman, T. J., Cuddihy, R. M., Scheitel, S. M., Naessens, J. M., Killian, J. M., & Pankratz, V. S. (2001) · Diabetes Care · doi:10.2337/diacare.24.12.2049 · Cited by 71
Vázquez‐Martín, A., Oliveras‐Ferraros, C., Barco, S. D., Martín-Castillo, B., & Menéndez, J. A. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.5456 · Cited by 35
Cited by
Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies
Tsilidis, K. K., Kasimis, J. C., Lopez, D. S., Ntzani, E. E., & Ioannidis, J. P. A. (2015) · BMJ · doi:10.1136/bmj.g7607 · Cited by 860
Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer
Sparano, J. A., Gray, R. J., Ravdin, P. M., Makower, D. F., Pritchard, K. I., Albain, K. S., Hayes, D. F., Geyer, C. E., Dees, E. C., Goetz, M. P., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1904819 · Cited by 532
Overcoming cancer therapeutic bottleneck by drug repurposing
Zhang, Z., Zhou, L., Xie, N., Nice, E. C., Zhang, T., Cui, Y., & Huang, C. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00213-8 · Cited by 516
Review: Diabetes, Obesity, and Cancer—Pathophysiology and Clinical Implications
Lega, I. C., & Lipscombe, L. L. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnz014 · Cited by 364
Metformin: Multi-faceted protection against cancer
Del Barco, S., Vazquez-Martin, A., Cufí, S., Oliveras-Ferraros, C., Bosch-Barrera, J., Joven, J., Martin-Castillo, B., & Menendez, J. A. (2011) · Oncotarget · doi:10.18632/oncotarget.387 · Cited by 302
Metadata
- Authors
- Peairs, K. S., Barone, B. B., Snyder, C. F., Yeh, H.-C., Stein, K. B., Derr, R. L., Brancati, F. L., & Wolff, A. C.
- Venue
- Journal of Clinical Oncology
- Published
- 2011-01-01
- Volume
- 29
- Issue
- 1
- Pages
- 40-46
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2096686828
- Cited by
- 449
- References
- 34
- FWCI
- 1.76
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.